Oral Abstract Session

Robert J. Motzer, Camillo Porta, Masatoshi Eto, et al. 
The authors conclude: LEN + PEMBRO demonstrated significant improvements in PFS, OS and ORR vs SUN. LEN + EVE demonstrated significant improvements in PFS and ORR vs SUN. Safety was manageable and consistent with the known single-agent profiles. Clinical trial information: NCT02811861.
Sumanta K. Pal, Catherine Tangen, Ian Murchie Thompson, et al.
The authors conclude: In this multi-arm randomized trial, only cabozantinib resulted in a statistically significant and clinically meaningful prolongation of PFS in pRCC patients compared to sunitinib. These data support cabozantinib as a reference standard for eligible patients with metastatic pRCC. Clinical trial information: NCT02761057.
Todd Michael Bauer, Toni K. Choueiri, Kyriakos P. Papadopoulos, et al.
The authors conclude: MK-6482 remained well tolerated with a favorable safety profile and promising single-agent activity in patients with ccRCC for all IMDC risk groups after further follow-up. A phase III trial in a similar population is underway. Clinical trial information: NCT02974738.
Toni K. Choueiri, Todd Michael Bauer, David F. McDermott, et al. 
The authors conclude: In this preliminary analysis, belzutifan in combination with cabozantinib demonstrated promising antitumor activity in previously treated pts with metastatic ccRCC. Safety was consistent with individual profiles of each agent. Clinical trial information: NCT03634540.